China Medipharm Insights - August 2000


USD 1,000.00

* Required Fields

USD 1,000.00


Be the first to review this product

Table of Contents

China Medipharm Insights - August 2000, China Medipharm InsightsMarket Analysis of China’s Biopharmaceutical Industry Market Analysis of China’s Biopharmaceutical Industry Three Types of Public Pharmaceutical CompaniesProduct NewsForlax Launched by Beaufour-Ipsen Antihyperlipidemic Lipobay Cleared for Marketing in ChinaSales Rights of Anti-obesity Qumei AuctionedFirst Gene Engineering Ophthalmic Drug ProducedVero Cell Encephalitis B Vaccine Listed as State Key ProjectAspartic Acid Lomefloxacin Put into ProductionDaktarin Package ChangedClonidine Controlled Release Patch Developed by 999 GroupNew Anti-hypertension Moxonidine LaunchedTrimebutine Maleate Tablets Begin ProductionJiayuan Pharma Launches P-hydroxyphenyl Glycine Dane Salt (E.K) Drug ConsumptionAnalysis of Antihyperlipidemic Drug MarketGeographic VariationCompany ProfilesZhejiang Hisun Escalates Fast999 Pharma Group Leads China’s Pharma IndustryLowers Cefotaxime Price by 65 PercentShandong Xinhua Pharma Expands GloballyEconomic Efficiency Improved in XinhuaRoche Zhongya Citrate Expands its ProductionJohnson-Shuguang TCM Research Center EstablishedBeijing Second Pharma Factory FlourishesDi’ao Group Booming on Hi-techJingxin Pharma Joins Hands with Shanghai Organic Chemistry Institute Beijing Medicines Corporation Strengthens Retail Chain ManagementBeijing Wohua Biotech Co EstablishedZhuhai United Pharma Targets OTC MarketsXi’an Cell Engineering Development Center Established Shanghai Bio-X Life Science Research Center EstablishedNortheast China Grand Pharmacy Chain Drugstores EstablishedGuilin Pavay Gene Pharma Expands Genetic Engineering Product LinesHaixing Sci&Tech Corporation Invests in BiopharmaChongqing Biological and Biochemical High Tech Development Park OpenedHubei Zenith Heilen Expands Shanghai Fuxing Raises Funds to ExpandShanghai New Asiatic PharmaHenan Xinyang Xinsheng PharmaRegulations & PoliciesAdministration of Foreign-Funded Joint Venture Hospitals EnforcedOTC Drug Evaluation And Registration Starts Out Regulations on Price Bidding for Unified Drug Procurement of Medical Institutions ReleasedFujian Initiates Health Insurance Reform Disease & Disease ControlMaternity Mortality Rate in ChinaLowered Forty Percent in Eight Years Pancreatic Cancer Trends Upward in ChinaBreast Disease On the Up TrendOne out of Five Residents in Beijing Has HypertensionNumber of People with Depression Increases in BeijingPancreatic Cancer Rises in WuhanChina Pays High Price for SmokingOphthalmic Disease Becoming a ThreatMarket AnalysisAnalysis of the Prospects of the China Pharma MarketOverview of the Current Chinese Pharma MarketNews in BriefFifty Percent of Chinese Patients Go to See DoctorsNationwide Drug Price Reduction BeginsDrug Prices Lowered in Shanghai; Jiangsu; Jilin and QinghaiImport & Export of TCM in 1999Drug Make Up 56 Percent of Medical Expenses in Tumor PatientsBeijing Focuses on Bioengineering and New Drug Development

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.